117 F. Supp. 3d 755
E.D. Va.2015Background
- UCB sued for declaratory judgment that its humanized monoclonal antibody product Cimzia® does not infringe Yeda’s U.S. Patent No. 6,090,923 (the '923 Patent) and that the patent is invalid; Yeda counterclaimed for infringement of claims 1, 5, and 9.
- The '923 Patent (filed claiming priority to Dec. 20, 1984; issued 2000) claims a “monoclonal antibody” that binds a human cytotoxin Yeda identifies as TNF and emphasizes hybridoma-produced (murine) antibodies in its specification.
- By 1984 hybridoma technology (mouse-derived) was the established method to produce monoclonal antibodies; chimeric and humanized antibodies emerged later (first humanized disclosure in 1986).
- The parties’ central dispute was claim construction: whether “monoclonal antibody” as of the patent’s effective filing date included genetically engineered chimeric or humanized antibodies like Cimzia®.
- The prosecution history shows Yeda sought to add claims covering chimeric/humanized antibodies in the 1990s, the PTO rejected those claims for written-description/enablement reasons, and Yeda cancelled them before allowance.
- The district court resolved claim construction and infringement on summary judgment, holding that Cimzia® neither literally infringes nor infringes under the doctrine of equivalents; other issues (validity, laches) were left undecided as moot.
Issues
| Issue | Plaintiff's Argument (UCB) | Defendant's Argument (Yeda) | Held |
|---|---|---|---|
| Meaning of “monoclonal antibody” (claim construction) | Term should be limited to antibodies produced via hybridoma (mouse-derived); did not include humanized antibodies in 1984 | Term’s plain meaning is broad (homogenous single-species antibody) and should include humanized/chimeric antibodies | “Monoclonal antibody” means a homogenous population of a single type produced via hybridoma and does not include chimeric or humanized antibodies (as of Dec. 1984) |
| Literal infringement of claims 1, 5, 9 by Cimzia® | Cimzia® is humanized so does not meet hybridoma limitation; no literal infringement | Cimzia® falls within the ordinary meaning of “monoclonal antibody” and thus literally infringes | No literal infringement — Cimzia® (humanized) does not meet the hybridoma-limited construction |
| Doctrine of equivalents (can Yeda assert humanized antibodies as equivalents) | Prosecution history estoppel bars equivalents because Yeda canceled claims to chimeric/humanized antibodies during prosecution | Cancellation did not relinquish equivalents; after-arising technology can be equivalent | Prosecution history estoppel applies; Yeda surrendered chimeric/humanized antibodies and cannot rely on doctrine of equivalents for Cimzia® |
| Use of extrinsic evidence (expert/dictionary/patents) to broaden claims | Extrinsic evidence cannot overcome intrinsic record showing hybridoma focus and lack of humanized antibodies in 1984 | Extrinsic sources show the term was understood broadly and later patent practice/dictionaries support inclusion | Extrinsic evidence was insufficient to overcome the intrinsic record and timing; intrinsic evidence controls (term limited to hybridoma-produced antibodies) |
Key Cases Cited
- Markman v. Westview Instruments, 517 U.S. 370 (1996) (claim construction is a question of law for the court)
- Phillips v. AWH Corp., 415 F.3d 1303 (Fed. Cir. 2005) (claim terms given their ordinary meaning to a person of skill at the time of invention; intrinsic evidence paramount)
- Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002) (prosecution history estoppel limits doctrine of equivalents after narrowing amendments)
- Chiron Corp. v. Genentech, 363 F.3d 1247 (Fed. Cir. 2004) (in 1984 the term “monoclonal antibody” referred to hybridoma-produced antibodies and did not encompass chimeric/humanized antibodies)
- Schriber-Schroth Co. v. Cleveland Trust Co., 311 U.S. 211 (1940) (claims must be read with reference to cancelled or rejected claims; surrendered subject matter cannot be recaptured by equivalents)